Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells.

International journal of molecular sciences - 9 Dec 2022

Vital Patrik da Silva, Bonatelli Murilo, Dias Marina Pereira, de Salis Larissa Vedovato Vilela, Pinto Mariana Tomazini, Baltazar Fátima, Maria-Engler Silvya Stuchi, Pinheiro Céline

Abstract excerpt

(1) BRAF mutations are associated with high mortality and are a substantial factor in therapeutic decisions. Therapies targeting BRAF-mutated tumors, such as vemurafenib (PLX), have significantly improved the overall survival of melanoma patients. However, patient relapse and low response rates remain challenging, even with contemporary therapeutic alternatives. Highly proliferative tumors often rely on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Proto-Oncogene Proteins B-raf
Share to Vemurafenib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to Neoplasm Recurrence, Local

Share to Phenotype

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 36555289
DOI: 10.3390/ijms232415650
PMCID: PMC9779063

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells.PMID 36555289Read ↗

Overcoming Chemoresistance to Vemurafenib in Melanoma via Targeted Inhibition of PCK1 Using 3-mercaptopropionic AcidSemantic proximity Read ↗

The BRAF Inhibitor Vemurafenib Activates Mitochondrial Metabolism and Inhibits Hyperpolarized Pyruvate-Lactate Exchange in BRAF-Mutant Human Melanoma Cells.Semantic proximity Read ↗

Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors.Semantic proximity Read ↗

Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.Semantic proximity Read ↗

Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.Semantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.Semantic proximity Read ↗

The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expressionSemantic proximity Read ↗

Pyruvate dehydrogenase inactivation causes glycolytic phenotype in BAP1 mutant uveal melanoma.Semantic proximity Read ↗

Relationship between melanoma vemurafenib tolerance thresholds and metabolic pathway choice and Wnt signaling involvementSemantic proximity Read ↗

Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH.Semantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.